Acrivon Therapeutics, Inc.

Develops precision cancer therapies by matching patients to drugs using its proteomics platform.

ACRV | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 480 ARSENAL WAY, SUITE 100, 2472 WATERTOWN
Website:: https://acrivon.com/
Sector:: Mining and quarrying
Industry:: Mining of non-ferrous metal ores

Description

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology. The company leverages its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to develop targeted cancer therapies. The AP3 platform utilizes phosphoproteomics to analyze the biologic drivers of a patient's cancer, enabling the creation of predictive 'OncoSignature' tests. This method is designed to match drug candidates with patients whose tumors are most likely to respond, aiming to improve therapeutic outcomes beyond what is achievable with genomics. Acrivon's pipeline is led by ACR-368, a selective kinase inhibitor in Phase 2 clinical trials for various solid tumors. The company also advances its internally developed programs and seeks strategic partnerships to apply its AP3 platform to co-develop predictive tests for external drug candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Acrivon Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Acrivon Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Acrivon Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Acticor Biotech Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.	France	ALACT
Acumen Pharmaceuticals, Inc. Clinical-stage biopharma developing an antibody therapy for Alzheimer's by targeting toxic AβOs.	United States of America	ABOS
Adaptive Biotechnologies Corp Maps immune genetics for blood cancer diagnostics and drug discovery partnerships.	United States of America	ADPT
Adecco Group AG Global talent solutions firm offering staffing, placement, career transition, and tech consulting.	Switzerland	ADI1
Adeia Inc. Invents and licenses foundational IP for the media and semiconductor industries.	United States of America	ADEA
ADforus Co., Ltd. Ad-tech firm with AI platforms for mobile marketing and publisher monetization solutions.	South Korea	397810
Aditxt, Inc. Acquires and develops biotech for autoimmunity, cancer detection, and neuro diagnostics.	United States of America	ADTX
Adocia Biotech improving protein drug formulations for diabetes & obesity and developing cell therapies.	France	ADOC
ad pepper media International N.V. Global performance marketing & audience targeting solutions for advertisers and agencies worldwide.	Germany	APM
Adtraction Group AB A partner marketing platform driving online sales for brands with a performance-based model.	Sweden	ADTR